Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives